Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LYNORAL vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LYNORAL is a progesterone receptor agonist that induces and maintains endometrial changes necessary for pregnancy support. It suppresses gonadotropin secretion, inhibiting ovulation, and alters cervical mucus consistency to impede sperm penetration.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Contraception (prevention of pregnancy),Endometriosis (off-label use for pain management),Dysfunctional uterine bleeding (off-label),Menstrual suppression (off-label),Hormone replacement therapy component (off-label)
Prevention of pregnancy (FDA-approved)
50 mg orally three times daily
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Terminal elimination half-life: 12–15 hours (11.2 ± 2.6 h in young adults; 14.8 ± 3.9 h in elderly), requiring once-daily dosing for steady-state within 4–7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes, forming conjugated metabolites (glucuronides and sulfates) that are excreted renally and fecally.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Renal: ~50% as unchanged drug; ~20% as glucuronide conjugates. Biliary/fecal: ~30% (including enterohepatic recirculation).
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
97–99% bound to plasma proteins, primarily albumin and α1-acid glycoprotein.
~99% bound to serum albumin and sex hormone-binding globulin.
0.8–1.0 L/kg (indicating extensive extravascular distribution, with significant tissue binding).
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: 65–75% (due to first-pass hepatic metabolism; Tmax 2–4 hours).
Oral: ~70% due to first-pass metabolism.
GFR 30-50 m L/min: 50 mg twice daily; GFR 15-29 m L/min: 50 mg once daily; GFR <15 m L/min: not recommended
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Child-Pugh class A: no adjustment; class B: 50 mg twice daily; class C: not recommended
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
2 mg/kg/dose orally three times daily; maximum 50 mg per dose
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Initiate at 25 mg twice daily; titrate slowly based on tolerance and renal function
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
LYNORAL carries a boxed warning for increased risk of thromboembolic disorders, including deep vein thrombosis and pulmonary embolism, especially in women with predisposing factors. Use is contraindicated in women with a history of or active thromboembolic disease.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Thromboembolic risk: Discontinue if signs of thrombosis occur.,Bone mineral density loss: Long-term use may decrease BMD; consider calcium/vitamin D supplementation.,Hepatic impairment: Use with caution in patients with liver disease; monitor liver function.,Breakthrough bleeding: May occur, especially in the first months of use.,Depression: Monitor for mood changes; discontinue if severe depression develops.,Cardiovascular effects: May increase risk of hypertension and lipid profile changes.
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Active or history of thromboembolic disorders (e.g., DVT, PE),Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Current or history of breast cancer (hormone-sensitive),Severe hepatic impairment or liver tumors,Hypersensitivity to LYNNORAL or any component
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Grapefruit juice may increase ethinylestradiol levels by inhibiting CYP3A4. Avoid excessive grapefruit consumption. St. John's Wort decreases effectiveness. No other significant food interactions.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
Lynoral (ethinyl estradiol) is contraindicated in pregnancy due to significant teratogenic risk. First trimester exposure increases risk of cardiovascular defects, neural tube defects, and limb reduction anomalies. Second and third trimester exposure may cause fetal feminization in males, urogenital abnormalities, and potential long-term reproductive tract effects. Use only after confirmed absence of pregnancy.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Ethinyl estradiol is excreted into breast milk with an M/P ratio of approximately 0.37 to 0.50. It may reduce milk production and composition, and expose the infant to estrogenic effects. Use during lactation is generally not recommended; alternative contraception is preferred.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
Lynoral is contraindicated in pregnancy; no dose adjustments are applicable. Pharmacokinetic changes such as increased clearance and volume of distribution occur in pregnancy, but the drug should not be used. If inadvertent exposure occurs, immediate discontinuation is required.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
Lynoral (ethinylestradiol) is a potent estrogen used primarily in oral contraceptives and hormone therapy. Monitor for thromboembolic events, especially in smokers over 35. Prescribe the lowest effective dose. Assess liver function periodically due to hepatic metabolism. Use with caution in patients with migraine with aura, hypertension, or history of cholestasis. Discontinue 4 weeks prior to elective surgery to reduce thrombotic risk.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take at the same time daily to maintain consistent hormone levels.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially over age 35.,Report symptoms of blood clots: leg pain/swelling, sudden chest pain, difficulty breathing, or vision changes.,May cause nausea; taking with food can help.,Antibiotics (e.g., rifampin) and certain anticonvulsants may reduce effectiveness; use additional contraception.,Do not use during pregnancy; if pregnancy is suspected, discontinue and consult doctor.,Regular blood pressure monitoring is recommended.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LYNORAL vs AFIRMELLE, answered by our medical review team.
LYNORAL is a Oral contraceptive that works by LYNORAL is a progesterone receptor agonist that induces and maintains endometrial changes necessary for pregnancy support. It suppresses gonadotropin secretion, inhibiting ovulation, and alters cervical mucus consistency to impede sperm penetration.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LYNORAL and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LYNORAL is: 50 mg orally three times daily. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LYNORAL and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LYNORAL is classified as Category C. Lynoral (ethinyl estradiol) is contraindicated in pregnancy due to significant teratogenic risk. First trimester exposure increases risk of cardiovascular defects, neural tube defe. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.